ES2493718T3 - Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil - Google Patents

Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil Download PDF

Info

Publication number
ES2493718T3
ES2493718T3 ES10700938.3T ES10700938T ES2493718T3 ES 2493718 T3 ES2493718 T3 ES 2493718T3 ES 10700938 T ES10700938 T ES 10700938T ES 2493718 T3 ES2493718 T3 ES 2493718T3
Authority
ES
Spain
Prior art keywords
combination
sgc
stimulators
activators
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10700938.3T
Other languages
English (en)
Inventor
Peter Sandner
Johannes-Peter Stasch
Michael-Friedrich BÖTTCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Application granted granted Critical
Publication of ES2493718T3 publication Critical patent/ES2493718T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Combinación de metil-4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]-5-pirimidinilcarbamato (4), y vardenafilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES10700938.3T 2009-01-17 2010-01-07 Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil Active ES2493718T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09000619 2009-01-17
EP09000619 2009-01-17
EP09002177 2009-02-17
EP09002177 2009-02-17
PCT/EP2010/000029 WO2010081647A2 (en) 2009-01-17 2010-01-07 Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
ES2493718T3 true ES2493718T3 (es) 2014-09-12

Family

ID=42153923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10700938.3T Active ES2493718T3 (es) 2009-01-17 2010-01-07 Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil

Country Status (20)

Country Link
US (2) US20120022028A1 (es)
EP (1) EP2387404B1 (es)
JP (1) JP5780430B2 (es)
KR (1) KR20110117655A (es)
CN (1) CN102316870A (es)
AU (1) AU2010205931A1 (es)
BR (1) BRPI1006869A2 (es)
CA (1) CA2749730C (es)
CL (1) CL2011001712A1 (es)
EA (1) EA201170942A1 (es)
ES (1) ES2493718T3 (es)
IL (1) IL213857A0 (es)
MA (1) MA32967B1 (es)
MX (1) MX2011007515A (es)
SG (1) SG172841A1 (es)
SV (1) SV2011003973A (es)
TN (1) TN2011000349A1 (es)
TW (1) TW201036971A (es)
WO (1) WO2010081647A2 (es)
ZA (1) ZA201105085B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095553A1 (en) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
AU2011257336B2 (en) 2010-05-26 2015-11-19 Adverio Pharma Gmbh The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).
US20130158028A1 (en) * 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013085276A1 (ko) * 2011-12-08 2013-06-13 에스케이케미칼 주식회사 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름
SG10201510668UA (en) * 2012-09-07 2016-01-28 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
AP2016009615A0 (en) 2014-07-22 2016-12-31 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ES2912648T3 (es) 2015-11-16 2022-05-26 Topadur Pharma Ag Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f] [1,2,4]triazinona como inhibidores de la fosfodiesterasa y usos de los mismos
BR112019024300A2 (pt) 2017-05-22 2020-06-16 Topadur Pharma Ag Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos
AU2019389263B2 (en) 2018-11-28 2025-05-22 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN110305837A (zh) * 2019-06-05 2019-10-08 西北师范大学 磷酸二酯酶5活性抑制剂作为诱导斑马鱼卵母细胞成熟的催熟剂的应用
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB369003A (en) 1931-03-25 1932-03-17 Richard Henry Sansome Improvements in fire extinguishing fluids
PL199236B1 (pl) * 1998-07-08 2008-08-29 Sanofi Aventis Deutschland N-Aryloamidy kwasów sulfonyloaminokarboksylowych podstawionych siarką, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie N-aryloamidów kwasów sulfonyloaminokarboksylowych podstawionych siarką
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
RU2009145935A (ru) * 2007-05-12 2011-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений

Also Published As

Publication number Publication date
KR20110117655A (ko) 2011-10-27
IL213857A0 (en) 2011-07-31
TN2011000349A1 (en) 2013-03-27
JP2012515176A (ja) 2012-07-05
CA2749730C (en) 2017-02-14
WO2010081647A3 (en) 2010-10-21
EP2387404B1 (en) 2014-06-25
AU2010205931A1 (en) 2011-07-28
CL2011001712A1 (es) 2012-04-09
CA2749730A1 (en) 2010-07-22
EP2387404A2 (en) 2011-11-23
TW201036971A (en) 2010-10-16
MX2011007515A (es) 2011-08-12
US20120022028A1 (en) 2012-01-26
JP5780430B2 (ja) 2015-09-16
MA32967B1 (fr) 2012-01-02
ZA201105085B (en) 2012-09-26
EA201170942A1 (ru) 2012-02-28
US20140288079A1 (en) 2014-09-25
BRPI1006869A2 (pt) 2016-03-15
CN102316870A (zh) 2012-01-11
SV2011003973A (es) 2011-12-06
WO2010081647A2 (en) 2010-07-22
SG172841A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
ES2493718T3 (es) Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil
TN2012000550A1 (en) THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
IL197243A0 (en) Pyrido (2,3-d)pyrimidinone compounds and their use as pi3 inhibitors
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
CY1124832T1 (el) 7-βενζυλο-4-(2-μεθυλοβενζυλο)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1 η)-ονη, τα αλατα της και οι μεθοδοι χρησης τους σε συνδυαστικη θεραπεια
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
MX2014010701A (es) Inhibidores de pirido [2,3-d] 2-amino, 6-fenil substituidos utiles como inhibidores de cinasa raf.
PH12012501217A1 (en) Beta-cell replication promoting compounds and methods of their use
EA201000775A1 (ru) Ингибиторы бета-лактамазы
CL2012002173A1 (es) Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
PL3357922T3 (pl) Pochodne 2-((5-(1-(3-(metylosulfonylo)propylo)piperydyn-4-ylo)pirydyn-2-ylo)amino)pirydo[2,3-d]pirymidyn-7(8h)-onu i związki pokrewne jako inhibitory cdk4 do leczenia nowotworów
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
SI2124944T1 (sl) Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
IL198461A (en) 3 alpha androstandiol and type 5 phosphodiesterase inhibitor (pde5 for on-demand use in the treatment of sexual dysfunction
CL2010001488A1 (es) Proceso para preparar 2,4-dioxo-1,2,4-tetrahidropirido[2,3-d]pirimidin-7-il-fenil sustituido y 2,4-bis[3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il-fenil-sustituido; sal fumarato de {5-[2,4-bis[(3s)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il]-2-metoxifenil}metanol; composicon farmaceutica; y uso para tratar el cancer.
MX2014015271A (es) Inhibidor de jak1 y jak2.
PH12017501121B1 (en) Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
UY32735A (es) Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales.
PH12012500955A1 (en) Drug combination with theobromine and its use in therapy
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
SI3774795T1 (sl) 4-(1H-imidazol-5-il)-1H-pirolo (2,3-B) piridini za uporabo pri zdravljenju levkemij, limfomov in trdnih tumorjev
CL2008003667A1 (es) Proceso de preparacion de etil-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4h-pirido[1,2-a]piridin-4-ona; y uno de los intermediarios considerados en el proceso descrito; util en la preparacion de paliperidona.
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).